targeting the underlying biology of aging itself
In the long human search for ways to slow the body's decline, a small California biotechnology company is preparing to make its case before the investment world. BioAge Labs, drawing on data from people who age with unusual grace, has built a pipeline of drug candidates aimed at the metabolic machinery of aging itself. Their appearance at a major healthcare conference in December marks a quiet but significant moment: the point where longevity science meets clinical reality, and where the question shifts from whether such an approach is possible to whether it is working.
- BioAge Labs' lead drug BGE-102 is in Phase 1 trials right now, with safety data expected before year-end — a ticking clock that gives the company's conference appearance real urgency.
- The NLRP3 inhibitor can cross the blood-brain barrier and be taken orally, positioning it as a potentially accessible treatment for obesity and cardiovascular risk — two of the most stubborn burdens in modern medicine.
- CEO Kristen Fortney and CFO Dov Goldstein will face investors and potential partners on December 4, making the case that aging biology — not just disease symptoms — is the right target for metabolic therapeutics.
- Beyond BGE-102, the company is advancing injectable and oral APJ agonists, signaling that this is a platform play, not a single-drug bet.
- The presentation will be webcast and archived, extending the company's reach beyond the conference room and into the broader conversation about where longevity science is headed.
BioAge Labs, a clinical-stage biotech headquartered in Emeryville, California, will travel to New York in December to present its approach to metabolic disease at the Piper Sandler 37th Annual Healthcare Conference. CEO and co-founder Kristen Fortney and CFO Dov Goldstein are scheduled for a fireside chat on December 4, with additional one-on-one meetings with investors and potential partners. A live webcast will be available, with recordings archived for 30 days.
At the center of BioAge's pitch is BGE-102, a small-molecule drug designed to inhibit NLRP3, a protein tied to inflammatory processes that contribute to obesity and cardiovascular risk. The compound is orally available and able to cross the blood-brain barrier — practical advantages for a drug targeting systemic metabolic conditions. A Phase 1 trial in healthy volunteers is underway, measuring single and multiple doses, with initial safety data expected before the end of the year.
The company's broader pipeline includes long-acting injectable formulations and oral compounds targeting the APJ receptor, another pathway implicated in metabolic regulation. What ties these candidates together is BioAge's proprietary discovery platform, built from data on people who age well and stay metabolically healthy — an attempt to understand aging not as a backdrop to disease, but as a mechanism to be directly addressed.
With clinical data imminent and a growing preclinical pipeline, BioAge's decision to step onto a major investment stage suggests the company believes it has reached a turning point. For those watching the aging-focused biotech space, the December presentation will offer an early read on whether the promise of longevity science is beginning to translate into something clinically — and commercially — real.
BioAge Labs, a clinical-stage biotechnology company based in Emeryville, California, is heading to New York next month to talk about its approach to treating metabolic disease by targeting the underlying biology of aging. The company announced this week that it will present at the Piper Sandler 37th Annual Healthcare Conference, scheduled for December 2 through 4, with leadership participating in a fireside chat on the final day.
The presentation will feature Kristen Fortney, the company's CEO and co-founder, alongside Dov Goldstein, who serves as chief financial officer. They are scheduled to sit down together on Thursday, December 4, from 1:30 to 1:55 p.m. Eastern time, and will also participate in individual meetings with investors and potential partners. The company plans to make a live webcast of the presentation available, with recordings archived on its investor relations website for 30 days after the event.
BioAge's central focus is on a drug candidate called BGE-102, a small-molecule inhibitor designed to block NLRP3, a protein involved in inflammatory processes. The compound is orally available and can cross the blood-brain barrier, making it suitable for treating obesity and cardiovascular risk factors. The company is currently running a Phase 1 trial measuring both single and multiple doses of the drug in healthy volunteers, with initial safety data expected before the year ends. This timeline puts the company on track to have concrete clinical information to share with the investment community in the coming weeks.
Beyond BGE-102, BioAge is developing additional therapeutic candidates, including long-acting injectable formulations and oral compounds that activate the APJ receptor, another target implicated in metabolic regulation and obesity. The company's drug discovery efforts rest on a proprietary platform built from human longevity data—essentially, insights gleaned from studying people who age well and remain metabolically healthy. This foundation allows the company to identify and pursue pathways that appear central to how the body ages metabolically, rather than relying solely on traditional disease models.
The decision to present at a major healthcare investment conference signals that BioAge believes it has reached a meaningful inflection point. With Phase 1 data imminent and a pipeline of follow-on candidates in preclinical development, the company is positioned to discuss not just its scientific rationale but also its near-term milestones and longer-term vision. For investors and potential pharmaceutical partners watching the aging-focused biotech space, this presentation offers a window into how one company is translating longevity science into clinical candidates—and whether that translation is working.
Notable Quotes
BioAge's discovery platform is built on human longevity data, allowing the company to identify pathways central to metabolic aging— Company description of its approach
The Hearth Conversation Another angle on the story
Why does a company focused on aging biology choose to present at a healthcare investment conference right now, in particular?
Because they have data coming. BGE-102's Phase 1 results are due before year-end. That's not a guess anymore—it's a concrete milestone. Investors and partners want to hear from companies when they have something new to say.
What makes BGE-102 different from other obesity drugs already on the market?
It's targeting a different mechanism. Most obesity drugs work on appetite or metabolism directly. BGE-102 is an NLRP3 inhibitor, which means it's addressing inflammation at a cellular level. The theory is that chronic inflammation drives metabolic aging. It's a more fundamental approach.
How does the company's longevity data platform actually work? What are they looking at?
They're studying people who age well—people who stay metabolically healthy into older age. Instead of asking what goes wrong in disease, they're asking what goes right in healthy aging. That flips the research question and can reveal pathways that traditional drug discovery misses.
Is there risk in this approach? What if the data doesn't pan out?
Always. Phase 1 is safety and tolerability. If BGE-102 causes unexpected side effects, the whole program stalls. But the company has enough confidence to move forward and enough capital to present publicly. That's a bet they're making.
What would success look like for BioAge in the next year?
Phase 1 data that's clean and shows the drug is well-tolerated. Then moving into Phase 2 trials in actual obese patients. And ideally, a partnership with a larger pharmaceutical company that can fund later-stage development. That's the path most biotech companies need to take.